Updated on 2 July 2013
Dassault Systèmes launched pharma solutions - Licensed to Cure for BioPharma
Singapore: Europe-based Dassault Systèmes, specializing in 3D design, 3D digital mock up and product lifecycle management (PLM) solutions, has launched a new industry solution experience for pharmaceutical and biotech companies named, Licensed to Cure for BioPharma.
Based on Dassault Systèmes' 3D Experience platform, the new solution transforms the way biotech and pharmaceutical companies manage product and process complexity by smoothing drug variation, enabling easier and faster expansion into new markets, all while managing increasing regulatory requirements.
Licensed to Cure for BioPharma boosts compliance strategies and creates a structured approach to manage product and process complexity, resulting in faster delivery of product variations to new markets. It results in global operational efficiency improvement, including maximizing supply chain opportunities, and enforcing efficient and compliant execution.
Dr Alan Louie, research director, IDC Health Insights, said that, "The ability to visualize a comprehensive holistic view of the full product portfolio is incredibly valuable. Systematically analyzing the likely impact of proposed changes prior to investing time and money, has the potential to deliver valuable insights to management that aren't available today."
Ms Monica Menghini, executive VP, industry and marketing, Dassault Systèmes, said that, "That comprehensive view of a biopharma company's current and past knowledge allows it to effectively introduce collaborative secured innovations. In the end, successful innovation and well-managed product and process complexity means faster drug introductions to more markets, therefore ultimately contributing an enhanced patient experience."